SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotify is rallying after its Q3 report, with traders focusing on premium subscriber growth, improving gross margin and a stronger Q4 profit outlook despite a revenue and EPS miss. Bulls see the forward guidance as the key signal, while bears question the spending and the sharp move higher despite the missed estimates.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASMLs quarterly results and outlook are driving attention: management described strong AI-related demand that could exceed planned equipment supply, while raising its sales outlook. The shares have nevertheless sold off, prompting debate over a sell the news reaction and whether elevated expectations, valuation concerns, or broader weakness in semiconductor stocks outweighed the upbeat demand signal.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevrons better-than-expected third-quarter results, particularly strong refining performance and record refinery throughput, are the main focus. Traders are celebrating the earnings beat and new highs, while some question whether elevated refining margins can last and whether the rally is overextended.

Texas Instruments Incorporated engages in the design and manufacture of semiconductors. It operates through the following segments: Analog, Embedded Processing, and Other. The Analog segment semiconductors change real-world signals, such as sound, temperature, pressure or images, by conditioning them, amplifying them and often converting them to a stream of digital data that can be processed by other semiconductors, such as embedded processors. The Embedded Processing segment involves handling specific tasks and can be optimized for various combinations of performance, power, and cost, depending on the application. The Other segment includes DLP products, calculators, and custom application-specific integrated circuits products. The company was founded in 1930 and is headquartered in Dallas, TX.

Texas Instruments Inc.

Texas Instruments strong Q3 results and above-consensus Q4 outlook are driving discussion, alongside the stocks recent rally and breakout. Traders are split between viewing the results and call buying as bullish and treating put activity and the pullback as hedging or profit-taking.

Generac Holdings, Inc. engages in the business of designing and manufacturing energy technology solutions. It operates under the Domestic and International segments. The Domestic segment includes the legacy Generac business and the acquisitions that are based in the United States and Canada. The International segment focuses on Generac business' Latin American export operations. The company was founded in 1959 and is headquartered in Waukesha, WI.

Generac Holdings Inc

Generacs quarterly results and its growing data-center business are the main focus, with traders highlighting the Amazon supply agreement and expanding backlog as support for its AI infrastructure story. Views are mixed: some see strong commercial growth and an earnings beat, while others point to a sales shortfall, unchanged full-year guidance, thinner commercial margins and profit-taking.

Compound (COMP) is a cryptocurrency and operates on the Ethereum platform. Compound has a current supply of 10,000,000 with 9,999,999.99995246 in circulation. The last known price of Compound is 20.49527411 USD and is down -2.02 over the last 24 hours. It is currently trading on 652 active market(s) with $25,001,434.49 traded over the last 24 hours. More information can be found at https://www.compound.xyz/.

Compound

Traders are focused on Compounds institutional-market rollout and reported treasury-backed expansion, which bulls see as a potential boost to its DeFi business. Others remain skeptical, pointing to COMPs weak performance versus other crypto assets and its difficulty sustaining gains.

Pyth Network (PYTH) is a cryptocurrency launched in 2021and operates on the Solana platform. Pyth Network has a current supply of 9,999,981,857.422035 with 7,874,958,864.894765 in circulation. The last known price of Pyth Network is 0.06503621 USD and is up 3.48 over the last 24 hours. It is currently trading on 450 active market(s) with $50,940,939.77 traded over the last 24 hours. More information can be found at https://pyth.network/.

Pyth Network

Discussion centers on Pyths revenue-linked buyback policy and Nasdaq data distribution, which traders cite as evidence of growing utility and RWA adoption. Optimism about a recovery and a teased quarterly announcement is tempered by concerns about token supply, volatility, and whether revenue-driven demand will be enough.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of Voceryq, a competing treatment for recurrent respiratory papillomatosis, has raised concerns about competition for Precigens PAPZIMEOS. Traders debate whether the rival will erode PAPZIMEOS sales, citing its potential to reduce surgeries while also pointing to Precigens first-mover advantage, full-approval status, and Inovios commercialization and funding challenges.

BNB (BNB) is a cryptocurrency . BNB has a current supply of 131,511,387.69. The last known price of BNB is 703.59425696 USD and is up 0.47 over the last 24 hours. It is currently trading on 3523 active market(s) with $2,735,089,335.64 traded over the last 24 hours. More information can be found at https://bnbchain.org/en.

Binance

Discussion is dominated by reports of a major Binance security breach and stolen crypto, prompting concerns about customer fund safety, suspended withdrawals, and possible spillover across crypto markets. Traders debate whether Binance can cover losses and whether the incident signals deeper exchange risks, while some point to frozen assets and the tokens relative resilience.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

UCO is drawing attention as crude oil trades on U.S.-Iran tensions and risks to Strait of Hormuz shipping, with traders debating whether supply disruptions will sustain prices or a diplomatic deal will unwind the risk premium. Bulls emphasize constrained supply and fuel shortages, while bears point to possible de-escalation, oversupply and inventory builds, and volatility decay in the leveraged fund.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Larimar (LRMR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

5 Small Drug Stocks Poised to Benefit From a Biotech Recovery

INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR PR Newswire NEW YORK, July 23, 2026 NEW YORK, July 23, 2026...

Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy

Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR PR Newswire NEW YORK, July 9, 2026 NEW YORK, July 9, 2026...

LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000

Equity

The shares were acquired in multiple transactions at prices ranging from $3.33 to $3.35 per share. 


LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns

H.C. Wainwright initiated coverage of Larimar with a ‘Buy’ rating and a $10 price target on Thursday.


INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR PR Newswire NEW YORK, July 1, 2026 NEW YORK, July 1, 2026...

Larimar Stock Slides 15% Despite FDA Backing Rolling Submission For Rare Disease Drug

Larimar Therapeutics Inc (LRMR) submits first module of Biologics License Application for investigational treatment for Friedreich's ataxia, with FDA support and positive long-term data showing durable safety profile and clinical improvements compared to natural history data.read more...

Larimar's Rare Disease Push Just Hit A Key Inflection Point — What Investors Need To Know

Larimar submitted the module of a rolling biologics license application to the U.S. Food and Drug Administration for the accelerated approval of nomlabofusp for Friedreich’s ataxia.

Larimar Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing treatments for patients suffering from complex rare diseases using a novel cell penetrating peptide technology platform. It also engages in the research, development, and commercialization of novel therapeutics for mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Following the transaction, Thomas E. Hamilton directly owns 714,798 shares.</li><li>Earlier this month, H.C. Wainwright initiated coverage of Larimar with a ‘Buy’ rating and a $10 price target.&nbsp;</li><li>H.C. Wainwright forecasts a commercial launch of Larimar’s nomlabofusp in 2027.</li></ul>Shares of Larimar Therapeutics, Inc. (LRMR) jumped 3% after hours on Wednesday after its director, Thomas E. Hamilton, purchased 50,000 shares of the company’s common stock.The shares were acquired in multiple transactions at prices ranging from $3.33 to $3.35 per share, for a weighted average price of $3.3378. The total value of the purchase was approximately $166,890.Following the transaction, Hamilton directly owns 714,798 shares. He also holds 159,433 shares indirectly through Post Edison, LLC.<h2 class="st-heading-2">Larimar Pipeline Development Efforts</h2>Larimar Therapeutics is a clinical-stage biotech company developing nomlabofusp, a potential treatment for Friedreich’s ataxia (FA). The company recently submitted the first module of a rolling Biologics License Application (BLA) to the FDA for accelerated approval.The remaining modules of the application are slated to be filed in the second half of the year.Earlier this month, H.C. Wainwright initiated coverage of Larimar with a ‘Buy’ rating and a $10 price target, highlighting the firm’s regulatory progress for nomlabofusp as a key driver of value.The analyst expects Larimar to submit its full Biologics License Application (BLA) for nomlabofusp later this year. The note stated the filing is likely to receive priority review from the FDA, which could shorten the standard review timeline and speed up a potential approval decision.H.C. Wainwright forecasts a commercial launch of nomlabofusp in 2027, with first-year U.S. sales of $47.9 million. The firm projects peak annual sales could exceed $1.1 billion by 2040, reflecting strong commercial potential in the rare disease space.<h2 class="st-heading-2">How Did LRMR Retail Traders React?</h2>On Stocktwits, retail sentiment around LRMR stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.A Stocktwits user highlighted that the director has “lot of shares” and has been putting in “real money” into the stock.<stembedurl>https://www.stocktwits.com/longterminvs/message/658598616</stembedurl>Another user focused on the company’s potential with regard to its pipeline and opined that if nomlabofusp is approved in Friedreich’s ataxia, it could open the “floodgates for reevaluation to the multibillion range.”<stembedurl>https://www.stocktwits.com/i_am_the_walrus_67/message/658548203</stembedurl><a href="https://stocktwits.com/symbol/LRMR">LRMR stock</a> has fallen by about 5% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/alhc-stock-clocks-worst-day-in-over-2-years-on-whistleblower-financial-manipulation-allegation/cZmn2r1R7VJ">ALHC Stock Clocks Worst Day In Over 2 Years On Whistleblower Financial Manipulation Allegation</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

The shares were acquired in multiple transactions at prices ranging from $3.33 to $3.35 per share. 

iShares Russell 2000 ETF

Vanguard Total Stock Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$2.47
Prev Close	$2.67
Open	$2.64
Dividend Yield	N/A
50-Day Moving Average	$3.21
Beta	1.62
Avg. Volume	1.38M
PE Ratio	-1.25

52-Week High	$6.42
52-Week Low	$1.92
Market Capitalization	$256.59M
EPS (Annual)	-$2.26
Price to Book	2.02
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

LRMR Fundamentals